Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estradiol Cypionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | MAPT | P10636 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.85 |
| ▸ | MEN1 | O00255 | 5/20 | 0.85 |
| ▸ | TP53 | P04637 | 3/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.85 |
| ▸ | PGR | P06401 | 2/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.85 |
| ▸ | AR | P10275 | 2/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.85 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.85 |
| ▸ | PDE4A | P27815 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estradiol Cypionate SCHEMBL29404977 | 0.92 | LMNA (1.00) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| Estradiol Cypionate SCHEMBL12754433 | 0.92 | LMNA (1.00) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| Estradiol Cypionate SCHEMBL41551 | 0.92 | LMNA (1.00) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| Estradiol Cypionate SCHEMBL19236258 | 0.92 | LMNA (1.00) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| Estradiol Cypionate SCHEMBL28333106 | 0.92 | LMNA (1.00) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| Estradiol Cypionate SCHEMBL20130822 | 0.92 | LMNA (1.00) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| Estradiol Cypionate SCHEMBL6195927 | 0.88 | LMNA (0.92) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| Estradiol Cypionate SCHEMBL3199191 | 0.86 | LMNA (0.87) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| SCHEMBL9404746 | 0.83 | MAPT (0.89) | LMNAMAPTKMT2ACYP3A4MEN1 | |
| SCHEMBL19393249 | 0.83 | MAPT (0.89) | LMNAMAPTKMT2ACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175872-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION | 2022-06-09 | — | — | US | disclosed |
| US-20190083574-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION (US) | 2019-03-21 | — | — | US | disclosed |
| US-10098967-B2 | Self-assembly of therapeutic agent-peptide nanostructures | OHIO STATE INNOVATION FOUNDATION (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2017172881-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-05 | — | — | WO | disclosed |
| EP-2847207-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | Aciex Therapeutics, Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140155577-A1 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2013169647-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | ACIEX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175872-A1 | THERMOGENIC COMPOSITIONS AND METHODS | LRBA, IAPP, FABP4 | ESR1 4034/4885LMNA 1305/4885MAPT 1286/4885 |
| US-20140155577-A1 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES | IAPP, TAP1, LNPEP | ESR1 3549/4885LMNA 1436/4885MAPT 268/4885 |
| US-10098967-B2 | Self-assembly of therapeutic agent-peptide nanostructures | IAPP, NPPA, TAP1 | ESR1 2801/4885LMNA 1534/4885MAPT 51/4885 |
| US-20190083574-A1 | THERMOGENIC COMPOSITIONS AND METHODS | LRBA, IAPP, FABP4 | ESR1 4034/4885LMNA 1305/4885MAPT 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.